Alixia was founded by Olof Mollstedt, Helen Chen in 2022.

Who are Alixia's investors?

Alixia's investors include Y Combinator, ZAKA VC.

How much funding has Alixia raised?

Alixia has disclosed $1.8M raised across 1 round.

Where is Alixia headquartered?

Alixia is headquartered in San Francisco, US.

Alixia

YC W22

San Francisco, US · Founded 2022 · Delaware corporation · 2 employees · 2 known investors

Find your way into Alixia

798 people in our graph share verified history with the Alixia team — schools, employers, funds. One of them is your warm intro.

Anthony Philippakisunlockedknows Helen Chen · together at Yale University (overlapped)

×10knows the team · via Y Combinator

knows the team · via StartX

Alixia develops therapeutics targeting tumor ecosystems to address cancer drug resistance and age-related diseases. The company integrates biology, biophysics, and computational chemistry to design compounds that disrupt metabolic and inflammatory triggers in multiple cell types within the tumor microenvironment.

Also known as Guided Clarity

Biotech Deep Tech Healthtech Medical Devices Therapeutics Drug discovery Oncology BiotechnologyUnited States of AmericaAmerica / Canada

Founders & leadership· Y Combinator alumni (W22)

Alixia was founded in 2022 by Olof Mollstedt and Helen Chen.

Olof MollstedtinCo-Founder

Helen Chen inCo-FounderHelen Chen is a researcher with expertise in cancer and aging biology who is now building Alixia.

Board

Sungwon LimBoard director

Investors · 2

Y CombinatorSan Francisco · $500K

ZAKA VCSan Francisco

Reported raises · per SEC filings

Form D private placements

$1.8M disclosed across 1 round · 2024

▶$1.8MraisedJul 2024 · 19 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Sungwon LimDirector
Lars Olof MollstedtExecutive Officer, Director
Helen Yee-Fang ChenExecutive Officer, Director

Offering amount: $3.5M
Amount sold: $1.8M
First sale: Jul 2024
Incorporated: Corporation, Delaware, 2022
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 5

by search overlap

Antheia, Inc.14 shared keywordsAntheia uses a yeast-based biosynthesis and fermentation platform to manufacture Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs) for essential medicines, offering an alternative to fragile agricultural sourcing. The company targets pharmaceutical supply chains, aiming to reduce drug shortages and improve reliability for medicines traditionally derived from plants.

Areteia Therapeutics11 shared keywordsAreteia Therapeutics was a clinical-stage biotechnology company that is no longer operating.

Lycia Therapeutics7 shared keywordsLycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation. Its targeted protein degradation platform, based on research from Carolyn Bertozzi's lab at Stanford, aims to address proteins previously considered undruggable.

IQVIA7 shared keywordsIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.

Intellia Therapeutics7 shared keywordsIntellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis. The company operates as a clinical-stage biopharmaceutical company pursuing potentially curative treatments from discovery through commercialization.

Companies competing with Alixia for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Alixia do?: Alixia develops therapeutics targeting tumor ecosystems to address cancer drug resistance and age-related diseases. The company integrates biology, biophysics, and computational chemistry to design compounds that disrupt metabolic and inflammatory triggers in multiple cell types within the tumor microenvironment.
Who founded Alixia?: Alixia was founded by Olof Mollstedt, Helen Chen in 2022.
Who are Alixia's investors?: Alixia's investors include Y Combinator, ZAKA VC.
How much funding has Alixia raised?: Alixia has disclosed $1.8M raised across 1 round.
Where is Alixia headquartered?: Alixia is headquartered in San Francisco, US.